Advertisement

Topics

In cancer immunotherapy, one PD-L1 test to rule them all?

23:58 EST 1 Dec 2016 | Topix

Clinical trials have proven the power of immunotherapies targeting PD-L1 or PD-1 in a range of cancers. However, these same trials show that only some patients benefit - tumors must depend on PD-L1 to be affected when medicines block its action.

Original Article: In cancer immunotherapy, one PD-L1 test to rule them all?

NEXT ARTICLE

More From BioPortfolio on "In cancer immunotherapy, one PD-L1 test to rule them all?"

Quick Search
Advertisement